Results 91 to 100 of about 4,051,537 (300)

Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome

British Journal of Clinical Pharmacology, EarlyView.
Aim This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids.
Maren Hermanns‐Clausen, Michaela Sommer, Annette Zschiesche, Verena Angerer, Martin Scheu, Florian Eyer, Johannes Nadler, Volker Auwärter   +7 more
wiley   +1 more source

Naltrexone Induced Serotonin Syndrome [PDF]

, 2013
Background: Serotonin syndrome resulted from hyperactivity of serotonin in nervous system and is potentially life threatening. Tramadol is known as one it's causing factors.
Behnoush, B, Memarian, A, Teimoory, M
core   +1 more source

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

British Journal of Clinical Pharmacology, EarlyView.
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask, Miina Lamminmäki, Olli Kampman, Mari Hämäläinen, Eeva Moilanen, Niko Seppälä, Anssi Solismaa   +6 more
wiley   +1 more source

Serotonin Syndrome Presenting as a Posterior Reversible Encephalopathy Syndrome

Case Reports in Neurology, 2020
Posterior reversible encephalopathy syndrome (PRES) is a neurological syndrome characterized by an altered level of consciousness, headaches, seizure, and visual changes. PRES has several different etiologies, including malignant hypertension, eclampsia,
Muhammad Taimur Malik, Mohammad Faraz Majeed, Ramin Zand   +2 more
doaj   +1 more source

Conundrums in neurology: diagnosing serotonin syndrome – a meta-analysis of cases

BMC Neurology, 2016
BackgroundSerotonin syndrome is a toxic state, caused by serotonin (5HT) excess in the central nervous system. Serotonin syndrome’s main feature is neuro-muscular hyperexcitability, which in many cases is mild but in some cases can become life ...
U. Werneke, Fariba Jamshidi, David Taylor, M. Ott   +3 more
semanticscholar   +1 more source

First time, low dose citalopram use-related serotonin syndrome

, 2007
Citalopram is a very potent and highly selective inhibitor of neuronal serotonin (5-hydroxytryptamine, or 5-HT). Serotonin syndrome is a rarely observed side-effect of citalopram use.
TÜREDİ, SÜLEYMAN, Eraydin, Ismet, Kalkan, Asim, GÜNDÜZ, ABDÜLKADİR, Hos, Ulku   +4 more
core   +1 more source

Environmental impact of antidepressants: Is a new prescription framework possible?

British Journal of Clinical Pharmacology, EarlyView.
Aims Antidepressants such as venlafaxine and sertraline pose high risks to water ecosystems. As depressive disorders and other mental health conditions become increasingly prevalent worldwide, prescription and environmental presence of these pharmaceuticals continue to rise. This study explores the practical viability of a new framework for prescribing
Matilde Bianconi, Valentina Giunchi, Michael Thiede, Elisa Sangiorgi, Marco Menchetti, Elisabetta Poluzzi   +5 more
wiley   +1 more source

Gabapentin as an add‐on analgesic to morphine in paediatric patients with chronic pain

British Journal of Clinical Pharmacology, EarlyView.
Aims Off‐label use of gabapentin for the treatment of chronic pain in children has increased over the last decade, with multiple clinical trials evaluating its role pain management and potential opioid‐sparing effects. To date, however, these studies appear to rely on empirical evidence without further consideration of pharmacokinetic‐pharmacodynamic ...
Paul Healy, Mariagrazia Felisi, Adriana Ceci, Oscar Della Pasqua, on Behalf of the GAPP Consortium, Corinne Alberti, Donato Bonifazi, Adriana Ceci, Thomas G. de Leeuw, Saskia N. de Wildt, Mariagrazia Felisi, Florentia Kaguelidou, Enora Le Roux, Rebecca Lundin, Laura Mangiarini, Dick Tibboel   +15 more
wiley   +1 more source

Translational development of crisugabalin for neuropathic pain

British Journal of Clinical Pharmacology, EarlyView.
Abstract Crisugabalin (HSK16149) is a next‐generation α2δ ligand developed to preserve the mechanistic rationale of gabapentinoids while refining target engagement and exposure‐related tolerability constraints. We performed a translational review of molecular/structural studies, in vivo pharmacology and behavioural safety assessments, phase I clinical ...
Rafael Batista João, Jilly Octoria Tagore Chan, Luísa Mendes Araújo, André Batista João, Raquel Mattos Filgueiras, Paulo César Ragazzo   +5 more
wiley   +1 more source

Overlapping of Serotonin Syndrome with Neuroleptic Malignant Syndrome due to Linezolid-Fluoxetine and Olanzapine-Metoclopramide Interactions: A Case Report of Two Serious Adverse Drug Effects Caused by Medication Reconciliation Failure on Hospital Admission

Case Reports in Medicine, 2016
Antipsychotic and antidepressant are often used in combination for the treatment of neuropsychiatric disorders. The concomitant use of antipsychotic and/or antidepressant with drugs that may interact can lead to rare, life‐threatening conditions such as ...
F. Mazhar, Shahzad Akram, Nafis Haider, R. Ahmed   +3 more
semanticscholar   +1 more source